US Stock Insider Trading | Roivant Sciences disclosed 6 insider trading transactions on February 23

K-LinePoet · 2026-02-26T10:31:42+00:00

On February 23, 2026, Roivant Sciences (ROIV) executive Torti Frank conducted multiple insider transactions, including selling 1.4 million shares and buying 3 million shares, with a significant total transaction amount. The company focuses on improving healthcare services and developing transformative drugs.

K-LinePoet

2026-02-26 10:31:42

Abstract generation in progress

On February 23, 2026, Roivant Sciences (ROIV) disclosed six insider trading transactions. Executive Torti Frank sold 1.4 million shares on February 23, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share (USD)	Total Amount (USD)
February 23, 2026	Executive	Torti Frank	February 23, 2026	Sell	587,400	27.51	$16,159,100
February 23, 2026	Executive	Torti Frank	February 23, 2026	Buy	3,000,000	3.85	$11,550,000
February 23, 2026	Executive	Torti Frank	February 19, 2026	Sell	1,400,000	27.42	$38,388,000
February 20, 2026	Executive	Torti Frank	February 20, 2026	Sell	1,012,600	27.15	$27,492,400
February 13, 2026	Executive	Venker Eric	February 13, 2026	Sell	200,000	26.49	$5,298,000
February 13, 2026	Executive	Venker Eric	February 13, 2026	Buy	200,000	3.85	$77,000
February 13, 2026	Shareholder	QVT Financial LP	February 13, 2026	Sell	225,000	26.50	$5,962,500
February 13, 2026	Shareholder	QVT Financial LP	February 13, 2026	Sell	150,800	26.49	$3,994,300
February 11, 2026	Shareholder	QVT Financial LP	February 13, 2026	Sell	425,000	26.67	$11,334,800
February 12, 2026	Director	Gold Daniel Allen, MANCHESTER KEITH S	February 12, 2026	Sell	300,000	26.72	$8,016,000

[Company Information]

Roivant Sciences Ltd. is a company incorporated in Bermuda on July 6, 2020. Roivant’s mission is to improve healthcare for patients by viewing every inefficiency as an opportunity. Roivant accelerates the development of transformative drugs by creatively building technology and cultivating talent, leveraging the Roivant platform to launch “Vants”—flexible and focused biopharmaceutical and health technology companies.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.